This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
HealthdirectFree Australian health advice you can count on. — Description, Dosage, Side Effects | PillsCard
OTC
HealthdirectFree Australian health advice you can count on.
50 mg/10.5mL, Injection, powder, lyophilized, for solution
INN: BRENTUXIMAB VEDOTIN
Available in:
🇬🇧🇫🇷🇵🇹
Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Dosage
50 mg/10.5mL
Route
INTRAVENOUS
Storage
—
About This Product
Manufacturer
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
SEAGEN INC.
ATC Code
L01FX05
Source
OPENFDA_NDC
(
ARTG
)
Hodgkin lymphoma,Treatment of patients with previously untreated CD30+ Stage III or Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD).,Treatment of adult patients with previously untreated CD30+ Stage IIB with large mediastinal mass and/or extranodal disease, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD).,Treatment of adult patients with CD30+ HL at higher risk of relapse or progression following ASCT.,Treatment of adult patients with relapsed or refractory CD30+ HL:,1. following autologous stem cell transplant (ASCT) or,2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.
Peripheral T-cell lymphoma,Treatment of adult patients with previously untreated CD30+ peripheral T-cell lymphoma (PTCL) in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).,Treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).,Cutaneous T cell lymphoma,Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.
⚠️ Warnings
• Caution should be exercised in patients with history of nerve problem, any allergy, who are taking other medications, during pregnancy and breastfeeding.
• It may cause dizziness, do not drive a car or operate machinery while taking this medication.
• It may decrease platelet counts; avoid injury or bruising.
• Avoid contact with people who have infections that may spread to others.
• Patient may develop with increased risk of tumor lysis syndrome (TLS), and viral brain infection (fatal conditions) with the following symptoms: irregular heartbeat, fainting, decreased urination, muscle weakness or cramps, dizziness, difficulty in talking, poor eyesight, nausea, vomiting, diarrhea, or loss of appetite; if it is so consult with your healthcare provider.
PillsCard reference image